TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39656628

Group type: EXPERIMENTAL
Intervention: Runcaciguat (30-120 mg once daily, titrated weekly)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 39656748

Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 3012

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3012
Study: 39656830

Group type: EXPERIMENTAL
Intervention: Filgotinib
Number of subjects: 1190
Study: 39656933

Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% eye drops twice daily for 4 weeks
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo eye drops twice daily for 4 weeks
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% eye drops
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 2500
Study: 39656951

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (ET)
Number of subjects: 4048

Group type: COMPARATOR
Intervention: Chemotherapy plus ET
Number of subjects: 4048
Study: 39657126

Group type: COMPARATOR
Intervention: Private institutions
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Public institutions
Number of subjects: 1029
Study: 39657168

Group type: EXPERIMENTAL
Intervention: LARKSPUR (web-based PA regulation intervention)
Number of subjects: 95

Group type: COMPARATOR
Intervention: emotion reporting/attention control
Number of subjects: 95
Study: 39657177

Group type: EXPERIMENTAL
Intervention: Presage Care monitoring system
Number of subjects: 118
Study: 39657179

Group type: EXPERIMENTAL
Intervention: Guided Tea Meditation (GTM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Breathing Meditation (BM)
Number of subjects: 100
Study: 39657205

Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing device
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard clamping and suturing techniques
Number of subjects: 95
Study: 39657224

Group type: EXPERIMENTAL
Intervention: Restrictive oxygen strategy (arterial oxygen saturation target of 94%)
Number of subjects: 1979

Group type: COMPARATOR
Intervention: Liberal oxygen strategy (12-15 L of oxygen per minute or fraction of inspired oxygen of 0.6-1.0)
Number of subjects: 1979

Group type: EXPERIMENTAL
Intervention: Restrictive oxygen strategy
Number of subjects: 1979

Group type: COMPARATOR
Intervention: Liberal oxygen strategy
Number of subjects: 1979
Study: 39657458

Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum hip extension
Number of subjects: 0
Study: 39657575

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole (palbociclib 125 mg on days 1-21 and letrozole 2.5 mg on days 1-28)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo plus letrozole (placebo on days 1-21 and letrozole 2.5 mg on days 1-28)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 77
Study: 39657693

Group type: EXPERIMENTAL
Intervention: Contemporary antiretroviral therapy (ART)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Multiomic analysis
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Lipidomic analysis
Number of subjects: 93
Study: 39657760

Group type: EXPERIMENTAL
Intervention: Team sport participation
Number of subjects: 184

Group type: COMPARATOR
Intervention: Individual physical activity
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control condition (date night)
Number of subjects: 184
Study: 39657845

Group type: EXPERIMENTAL
Intervention: Instant message rehabilitation intervention over six months in addition to standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instant message rehabilitation intervention
Number of subjects: 0
Study: 39657981

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO)
Number of subjects: 1766

Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 1766
Study: 39657989

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 571

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study: 39658013

Group type: EXPERIMENTAL
Intervention: Family-centered empowerment model intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 68
Study: 39658198

Group type: EXPERIMENTAL
Intervention: Rare 22q11.2 copy number variants (CNVs) detected through whole genome microarray genotyping.
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Rare 22q11.2 CNVs
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: CNV screening
Number of subjects: 272

Group type: COMPARATOR
Intervention: CNV burden in EBAV cohort
Number of subjects: 272
Study: 39658277

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) administration in high-risk pregnancies
Number of subjects: 58

Group type: COMPARATOR
Intervention: Low-dose aspirin (previous study comparison group)
Number of subjects: 58
Study: 39658315

Group type: EXPERIMENTAL
Intervention: Higher blood pressure target (77 mmHg)
Number of subjects: 789

Group type: COMPARATOR
Intervention: Lower blood pressure target (63 mmHg)
Number of subjects: 789
Study: 39658326

Group type: EXPERIMENTAL
Intervention: Rituximab (1g on days 1, 15, and 180±7)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 37
Study: 39658608

Group type: EXPERIMENTAL
Intervention: Alternating modified CAPOX (capecitabine 1000 mg/m² and oxaliplatin) plus bevacizumab (anti-VEGF-A antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternating modified CAPIRI (capecitabine and irinotecan) plus bevacizumab (anti-VEGF-A antibody)
Number of subjects: 0
Study: 39658784

Group type: EXPERIMENTAL
Intervention: Tailored internet-delivered cognitive behavior therapy (ICBT) for 10 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Active control group (non-directive support) for 10 weeks
Number of subjects: 101
Study: 39658862

Group type: EXPERIMENTAL
Intervention: Electronic sepsis screening
Number of subjects: 60055

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 60055
Study: 39659090

Group type: EXPERIMENTAL
Intervention: MV-PCI
Number of subjects: 8138

Group type: COMPARATOR
Intervention: CV-PCI
Number of subjects: 8138
Study: 39659276

Group type: EXPERIMENTAL
Intervention: active rTMS + active rSMS
Number of subjects: 42

Group type: COMPARATOR
Intervention: active rTMS + sham rSMS
Number of subjects: 42
Study: 39659429

Group type: EXPERIMENTAL
Intervention: Dietary or pharmacologic iron restriction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical evidence from case reports and small case series studies
Number of subjects: 0
Study: 39659870

Group type: EXPERIMENTAL
Intervention: Application Plus Online Therapist Support Group (AT + OT Group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Application Only Group (Group A)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Waitlist Control Group (WLC Group)
Number of subjects: 105
Study: 39660140

Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccine
Number of subjects: 26
Study: 39660637

Group type: EXPERIMENTAL
Intervention: Mepolizumab (anti-interleukin-5 monoclonal antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39660725

Group type: EXPERIMENTAL
Intervention: 6-min pegboard and ring test (6PBRT)
Number of subjects: 22
Study: 39660783

Group type: EXPERIMENTAL
Intervention: CMD-positive patients
Number of subjects: 262
Study: 39660834

Group type: EXPERIMENTAL
Intervention: Imlunestrant
Number of subjects: 874

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Imlunestrant-abemaciclib
Number of subjects: 874
Study: 39660861

Group type: EXPERIMENTAL
Intervention: Teclistamab 1.5 mg/kg subcutaneously weekly after step-up dosing
Number of subjects: 26
Study: 39660994

Group type: EXPERIMENTAL
Intervention: FHD-609 (5 to 80 mg BIW; n=40)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: FHD-609 (40 to 120 mg QW; n=15)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: FHD-609
Number of subjects: 55
Study: 39661074

Group type: EXPERIMENTAL
Intervention: Social risk factors (SRFs) affecting care
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lower income participants
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Participants lost to follow-up (LTFU)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Accessibility as a P-T domain
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Distance to appointment as an SRF
Number of subjects: 100
Study: 39661119

Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg/day
Number of subjects: 3668

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3668
Study: 39661178

Group type: EXPERIMENTAL
Intervention: Scheimpflug imaging (Pentacam HR, Oculus)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Swept source AS-OCT (Casia SS-1000 Tomey)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Both devices (Scheimpflug and AS-OCT)
Number of subjects: 81
Study: 39661358

Group type: EXPERIMENTAL
Intervention: Guselkumab treatment
Number of subjects: 211
Study: 39661372

Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg per day)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 558

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 558
Study: 39661388

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonist (specific dosage and duration not provided)
Number of subjects: 4334

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 4334
Study: 39661440

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) session of 30 minutes
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Control group without added MI
Number of subjects: 327
Study: 39661851

Group type: EXPERIMENTAL
Intervention: Observational study
Number of subjects: 415
Study: 39661923

Group type: EXPERIMENTAL
Intervention: Nivolumab plus doxorubicin, vinblastine, dacarbazine (N-AVD)
Number of subjects: 40
Study: 39661957

Group type: EXPERIMENTAL
Intervention: 9-month, mobile phone-delivered, family-focused, self-care support intervention
Number of subjects: 318

Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 318
Study: 39661964

Group type: EXPERIMENTAL
Intervention: Inhaled long-acting beta-2 agonists (LABAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-acting beta-2 agonists (SABAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-LABA users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Days SABAs were used
Number of subjects: 0
Study: 39662163

Group type: EXPERIMENTAL
Intervention: Opicinumab 100 mg/kg intravenously once every 4 weeks from baseline to Week 20
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo intravenously once every 4 weeks from baseline to Week 20
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Opicinumab (mfVEP substudy)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (mfVEP substudy)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Opicinumab
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 39662304

Group type: EXPERIMENTAL
Intervention: CIT (5.3 g of CIT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CMA (5.3 g of CIT, 2.7 g of malate)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 39662486

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine with rituximab
Number of subjects: 39
Study: 39662676

Group type: EXPERIMENTAL
Intervention: Complementary food supplements (CFSs) with caregiver nutrition counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (counseling alone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CFSs
Number of subjects: 0
Study: 39662698

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Nifedipine ER
Number of subjects: 132
Study: 39663002

Group type: EXPERIMENTAL
Intervention: Testing frequency of one time per year
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Testing frequency of two times per year
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Testing frequency of three times per year
Number of subjects: 201
Study: 39663060

Group type: EXPERIMENTAL
Intervention: K-Clip transcatheter tricuspid annuloplasty system
Number of subjects: 96
Study: 39663161

Group type: EXPERIMENTAL
Intervention: Attend-PE model (structured integrated post-pulmonary embolism follow-up care model)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2000
Study: 39663160

Group type: EXPERIMENTAL
Intervention: Adductor-psoas tenotomy + Temporary Medial Hemiepiphysiodesis of the Proximal Femur (TMH-PF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adductor-psoas tenotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adductor-psoas tenotomy + TMH-PF
Number of subjects: 0
Study: 39663170

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation combined with ERAS (PREERAS) management
Number of subjects: 164

Group type: COMPARATOR
Intervention: Regular preadmission education and perioperative ERAS care
Number of subjects: 164
Study: 39663172

Group type: COMPARATOR
Intervention: Debridement of central or radial tear
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repair of peripheral tear
Number of subjects: 0
Study: 39663175

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 719
Study: 39663378

Group type: EXPERIMENTAL
Intervention: Seltorexant 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seltorexant 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39663512

Group type: EXPERIMENTAL
Intervention: Awake prone positioning (APP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 39663544

Group type: EXPERIMENTAL
Intervention: Mandala coloring plus antenatal education
Number of subjects: 140

Group type: COMPARATOR
Intervention: Antenatal education alone
Number of subjects: 140
Study: 39663755

Group type: EXPERIMENTAL
Intervention: Care4Today Connect (C4T CAD-PAD) mobile application
Number of subjects: 271
Study: 39664091

Group type: EXPERIMENTAL
Intervention: Educational intervention by midwives (theoretical and practical knowledge)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Educational intervention by midwives (breastfeeding management)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Educational intervention by midwives (self-esteem and commitment)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Midwives' motivation to use appropriate teaching strategies
Number of subjects: 53
Study: 39664231

Group type: EXPERIMENTAL
Intervention: Prucalopride (1 or 2 mg once daily)
Number of subjects: 2484

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2484
Study: 39664752

Group type: EXPERIMENTAL
Intervention: Oxaloacetate (2,000 mg per day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control
Number of subjects: 82
Study: 39664767

Group type: EXPERIMENTAL
Intervention: Nutrition counseling intervention (six theoretical and practical workshops on food and nutrition education over 4 months)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 158
Study: 39664835

Group type: EXPERIMENTAL
Intervention: Ultraconservative treatment (UCT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 135
Study: 39665054

Group type: EXPERIMENTAL
Intervention: Vitalthings Guardian M10 (contactless patient monitor)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nox T3s (reference device)
Number of subjects: 32
Study: 39665235

Group type: EXPERIMENTAL
Intervention: ACM-001.1 15 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pindolol 30 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pindolol 20 mg twice-daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ACM-001.1 5, 10 or 15 mg twice-daily for 4 days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pindolol 15 mg
Number of subjects: 51
Study: 39665378

Group type: COMPARATOR
Intervention: Implementation strategies (e.g. educational materials, educational meetings, education outreach visits)
Number of subjects: 6489
Study: 39665482

Group type: EXPERIMENTAL
Intervention: 2-slot brackets with an integral base
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional twin brackets with foil mesh
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bracket removal pliers
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lift-Off Debonding Instrument
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adhesive removal methods involving rotary instruments
Number of subjects: 100
Study: 39665506

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 39665575

Group type: EXPERIMENTAL
Intervention: Treatment for metabolic acidosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 39665585

Group type: EXPERIMENTAL
Intervention: Active monitoring (follow-up every 6 months with breast imaging and physical examination; n=484)
Number of subjects: 995

Group type: COMPARATOR
Intervention: Guideline-concordant care (surgery with or without radiation therapy; n=473)
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 995

Group type: COMPARATOR
Intervention: Guideline-concordant care
Number of subjects: 995
Study: 39665588

Group type: COMPARATOR
Intervention: Guideline-concordant care (GCC)
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Active monitoring (AM)
Number of subjects: 957
Study: 39665621

Group type: EXPERIMENTAL
Intervention: CHIP
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: mLOY
Number of subjects: 446
Study: 39665633

Group type: EXPERIMENTAL
Intervention: Single-phase CT
Number of subjects: 8893

Group type: EXPERIMENTAL
Intervention: Inspiratory CT
Number of subjects: 8893

Group type: EXPERIMENTAL
Intervention: Expiratory CT
Number of subjects: 8893

Group type: EXPERIMENTAL
Intervention: Clinical data
Number of subjects: 8893
Study: 39665649

Group type: EXPERIMENTAL
Intervention: Omission of axillary surgery (surgery-omission group)
Number of subjects: 4858

Group type: COMPARATOR
Intervention: Sentinel-lymph-node biopsy (surgery group)
Number of subjects: 4858
Study: 39665652

Group type: EXPERIMENTAL
Intervention: Bedaquiline monotherapy for 8 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard multidrug therapy (as defined by the World Health Organization) after 8 weeks of bedaquiline
Number of subjects: 9
Study: 39665701

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 6001

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study: 39665734

Group type: EXPERIMENTAL
Intervention: Calls only
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Calls+mHealth
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Calls+NRT
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Calls+NRT+mHealth
Number of subjects: 508

Group type: COMPARATOR
Intervention: No-mailed NRT
Number of subjects: 508

Group type: COMPARATOR
Intervention: Mailed NRT
Number of subjects: 508

Group type: COMPARATOR
Intervention: Mailed NRT vs No-mailed NRT
Number of subjects: 508

Group type: COMPARATOR
Intervention: mHealth vs No mHealth
Number of subjects: 508
Study: 39665770

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg on days 1 and 8 of a 21-day cycle
Number of subjects: 43
Study: 39665869

Group type: EXPERIMENTAL
Intervention: 2% cholic acid (CA)-supplemented chow for 7 days
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: PIZZ subjects
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Hepatocytes with AAT aggregates
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: PiZ overexpression in cultured cells/primary hepatocytes
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (19 subjects)
Number of subjects: 76
Study: 39666075

Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both TKA and UKA
Number of subjects: 115
Study: 39666143

Group type: EXPERIMENTAL
Intervention: Eptinezumab treatment
Number of subjects: 1072
Study: 39666249

Group type: EXPERIMENTAL
Intervention: Clareon CNA0T0 intraocular lens (IOL)
Number of subjects: 49
Study: 39666256

Group type: EXPERIMENTAL
Intervention: Appropriate DOAC dosing
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: DOAC underdosing predictors
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Correct DOAC dosing predictors
Number of subjects: 866
Study: 39666392

Group type: EXPERIMENTAL
Intervention: Reinfection group (3 exposures to 20 male cercariae)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Infection control group (2 mock exposures with water)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Reinfection group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Infection control group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 39666396

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 booster dose
Number of subjects: 3793

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3793

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 primary series
Number of subjects: 3793

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Number of subjects: 3793
Study: 39666443

Group type: EXPERIMENTAL
Intervention: BF-200 ALA
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 39666490

Group type: EXPERIMENTAL
Intervention: One-to-one music therapy (MT) intervention for 16 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Active control group receiving storytelling
Number of subjects: 42
Study: 39666517

Group type: EXPERIMENTAL
Intervention: VIA Family
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 95